C21 Capsule Composition for Lung Disease Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF), are limited in effectiveness and stability, with existing drug formulations like pirfenidone and nintedanib causing side effects and being difficult to stabilize due to sensitivity to light and water, making them challenging for commercial viability and patient use.
Innovation Solution
A pharmaceutical dosage form comprising a heterogeneous mixture of C21, a selective AT2 receptor agonist, suspended in a pharmaceutically-acceptable, hydrophobic lipid-based carrier, encapsulated in soft-shell gelatin capsules to ensure stability and solubility, minimizing exposure to water and light, thereby maintaining efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If C21 is formulated in conventional aqueous solutions, then it can be easily administered, but it becomes unstable due to sensitivity to light and water
Solution Approach 1:
The patent formulates C21 in a lipid-based carrier system that creates a hydrophobic, water-free environment. This inert environment protects the light- and water-sensitive C21 from degradation while maintaining administerability through oral capsule delivery. The lipid carrier acts as a protective matrix that isolates the active ingredient from harmful aqueous and光照 conditions.
Solution Approach 2:
The patent changes the physical and chemical parameters of the formulation medium from aqueous to lipid-based. By transitioning from water-based solutions to oil-based carriers, the formulation achieves compatibility with light- and water-sensitive C21 while maintaining bioavailability through appropriate lipid selection and capsule delivery systems.
2Reliability
If C21 is suspended in lipid-based carriers, then stability is improved, but solubility becomes challenging
Solution Approach 1:
The patent employs composite lipid-based carrier systems combining multiple lipid components with complementary properties. These composite formulations achieve both the hydrophobic protection needed for stability and the appropriate solubilizing characteristics for drug delivery. The composite nature allows optimization of both stability and solubility parameters simultaneously.
3Adaptability or versatility
If existing drugs like pirfenidone and nintedanib are used, then treatment options are available, but they cause side effects and have commercial viability challenges
Solution Approach 1:
The lipid-based carrier system serves as an intermediary delivery vehicle that enables controlled release and protection of C21. This intermediary system allows the active ingredient to reach its target in the lung tissue while minimizing systemic exposure that causes side effects. The carrier mediates between the drug and the body, improving the therapeutic index.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dosage form provides a stable, effective, and commercially viable treatment for ILDs by maintaining the integrity and bioactivity of C21, reducing side effects, and allowing for consistent and uniform drug delivery, thereby improving patient outcomes and treatment accessibility.
Implementation Method 1
a pharmaceutically-acceptable, hydrophobic, lipid-based carrier in which C21 or salt thereof is essentially insoluble
Implementation Method 2
a heterogeneous mixture comprising solid particles of C21, or a pharmaceutically-acceptable salt thereof, suspended in a pharmaceutically-acceptable, hydrophobic, lipid-based carrier
Data Source
AI summary
According to the invention there is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a heterogeneous mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, suspended in a pharmaceutically-acceptable, hydrophobic, lipid-based carrier in which C21 or salt thereof is essentially insoluble, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carriers include triglycerides. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.